These advancements of the tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which target the epidermal growth factor receptor (EGFR), have led us to personalize the treatment of EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC) [4,5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.